Maitalon 30/21+7 (Drospirenone, Ethinylestradiol | Lactose Anhydrous)

The two hormones in the tablet act together to suppress the mid‑cycle surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH), which stops ovulation. Drospirenone also thickens cervical mucus and alters the endometrium, while ethinylestradiol stabilises the uterine lining, reducing the chance of fertilisation and implantation.

The dosing regimen for Maitalon 30/21+7 is determined by the prescribing clinician. Typically, the product is taken once daily for 21 active tablets followed by a 7‑day hormone‑free interval, but the exact schedule should be confirmed with a qualified healthcare professional.

Maitalon 30/21+7 is contraindicated during pregnancy because it is intended to prevent conception. If pregnancy occurs, the tablet should be stopped immediately. Limited data exist for use while breastfeeding; clinicians usually advise against continued use until after the postpartum period, unless the benefits outweigh potential risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maitalon 30/21+7 contains drospirenone, a progestin with anti‑mineralocorticoid activity, which may result in less water retention compared with some other progestins. Its estrogen component, ethinylestradiol, is standard across many combined pills, offering comparable efficacy while the specific side‑effect profile may differ.

The tablets should be stored at room temperature, below 25 °C, in the original blister pack to protect them from moisture and light. Keep the container tightly closed and out of reach of children. Do not refrigerate or freeze the product.

Maitalon 30/21+7 is taken orally, usually with water, once each day at the same time. The typical regimen consists of 21 consecutive active tablets followed by a 7‑day hormone‑free interval during which a withdrawal bleed occurs. Adherence to the daily schedule is essential for optimal effectiveness.

Serious risks include thromboembolic events such as deep‑vein thrombosis, pulmonary embolism, stroke, and myocardial infarction, especially in smokers over 35 or women with pre‑existing clotting disorders. Severe hypertension and rare liver tumors have also been reported. Prompt medical attention is required if any warning signs appear.

Women with a history of venous or arterial thromboembolism, current pregnancy, known or suspected breast cancer, uncontrolled hypertension, severe liver disease, or those who smoke heavily (more than 15 cigarettes per day) and are over 35 years old should avoid using this contraceptive. A thorough medical assessment is essential before initiation.